Development of a Nose Cream Containing the Synthetic Antimicrobial Peptide P60.4Ac for Eradication of Methicillin-Resistant Staphylococcus aureus Carriage.
Göblyös A, Schimmel KJ, Valentijn AR, Fathers LM, Cordfunke RA, Chan HL, Oostendorp J, Nibbering PH, Drijfhout JW, Hiemstra PS, Hartigh JD.
J Pharm Sci. 2013 Aug 17. doi: 10.1002/jps.23695. [Epub ahead of print]
Methicillin-resistant Staphylococcus aureus (MRSA) infections are an increasing problem, and current treatment options are suboptimal. Nasal carriage of MRSA is a major risk factor for infection, but nasal eradication strategies are increasingly considered to be insufficiently effective. In this study, a water-in-oil cream formulation was developed for nasal application with an antimicrobial peptide, P60.4Ac, aimed at the eradication of MRSA carriage. Quality control of the cream included the measurement of the content and release of the peptide by a validated high-performance liquid chromatography method. Stability of the peptide in the formulation was investigated including the evaluation of the effect of stress conditions. Preliminary shelf-life study of the drug formulation demonstrated that the peptide is stable in the formulation at least for 5 months. Microbial-killing assays with MRSA LUH14616 as a target demonstrated the dose-dependent antimicrobial activity of the peptide formulation. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
Keyword: Peptide API Powder